Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of CV0501 COVID-19 Booster in Adults
NCT05477186Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- mRNA Therapeutics
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of CV0501 in coronavirus disease 2019 (COVID-19), sponsored by GSK. Primary endpoints: Number of Participants With Solicited Local Adverse Events at 7 days, Number of Participants With Solicited Systemic Adverse Events at 7 days and 5 more. Started Aug 2022; status: completed.
02
Drugs
CV0501
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05477186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477186.